Charles Schwab Investment Management Inc. Reduces Stake in Keros Therapeutics, Inc. $KROS

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Keros Therapeutics by 13.5%, selling 37,759 shares and now holding approximately 241,923 shares worth $2.47 million.
• Analysts have varying price targets for Keros Therapeutics, with a consensus average target price of $30.00 and ratings ranging from "Buy" to "Neutral."
• Keros Therapeutics reported an earnings per share of ($0.76), surpassing expectations, but with a significantly lower revenue than anticipated, leading to a forecast of -4.74 earnings per share for the current fiscal year.

Charles Schwab Investment Management Inc. lessened its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 13.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 241,923 shares of the company's stock after selling 37,759 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.60% of Keros Therapeutics worth $2,465,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Keros Therapeutics by 31.1% in the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company's stock valued at $26,151,000 after purchasing an additional 609,212 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Keros Therapeutics in the 1st quarter valued at $490,000. Federated Hermes Inc. lifted its stake in shares of Keros Therapeutics by 882.3% in the 1st quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company's stock valued at $12,474,000 after purchasing an additional 1,099,519 shares during the last quarter. Corton Capital Inc. acquired a new position in shares of Keros Therapeutics in the 1st quarter valued at $186,000. Finally, CWM LLC lifted its stake in shares of Keros Therapeutics by 10,157.7% in the 1st quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after purchasing an additional 2,641 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Scotiabank decreased their price target on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research note on Monday, May 12th. Bank of America downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. Wedbush reiterated a "neutral" rating and issued a $15.00 price objective on shares of Keros Therapeutics in a report on Friday, May 30th. Finally, HC Wainwright cut their price objective on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Seven analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $30.00.

Keros Therapeutics Price Performance

Shares of KROS traded up $0.11 during mid-day trading on Wednesday, reaching $15.83. The company's stock had a trading volume of 97,385 shares, compared to its average volume of 953,997. Keros Therapeutics, Inc. has a 12-month low of $9.12 and a 12-month high of $72.37. The stock has a market cap of $642.81 million, a PE ratio of 51.06, a price-to-earnings-growth ratio of 1.96 and a beta of 1.06. The company's 50 day moving average is $14.26 and its 200 day moving average is $13.23.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, beating analysts' consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $3.83 million. During the same quarter in the prior year, the business posted ($1.25) EPS. The business's revenue for the quarter was up 49002.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.